Will Brii join the IPO frenzy?
Brii Biosciences is also mulling a listing in Hong Kong, Bloomberg reported, citing sources familiar with the situation.
The China-focused biotech is said to be working with investment banks on an IPO that could raise between $200 million and $400 million. The company is also seeking about $100 million from private investors in a pre-IPO round, sources told Bloomberg.
Founded just two years ago, Brii focuses on developing therapies for infectious diseases such as hepatitis B and HIV. In March, the company partnered with Tsinghua University and Shenzhen’s Third People’s Hospital to develop two potential monoclonal antibody treatments for Covid-19.
The China-focused biotech is said to be working with investment banks on an IPO that could raise between $200 million and $400 million. The company is also seeking about $100 million from private investors in a pre-IPO round, sources told Bloomberg.
Founded just two years ago, Brii focuses on developing therapies for infectious diseases such as hepatitis B and HIV. In March, the company partnered with Tsinghua University and Shenzhen’s Third People’s Hospital to develop two potential monoclonal antibody treatments for Covid-19.
No hay comentarios:
Publicar un comentario